Galera Therapeutics (GRTX)
(Delayed Data from OTC)
$0.08 USD
0.00 (-0.63%)
Updated Sep 19, 2024 03:32 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Galera Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 49 | 51 | 73 | 71 | 51 |
Income After Depreciation & Amortization | -49 | -51 | -73 | -71 | -51 |
Non-Operating Income | 2 | 1 | 0 | 1 | 2 |
Interest Expense | 11 | 12 | 7 | 5 | 3 |
Pretax Income | -59 | -62 | -81 | -74 | -52 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -59 | -62 | -81 | -74 | -52 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -59 | -62 | -81 | -74 | -52 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -49 | -51 | -73 | -70 | -50 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -49 | -51 | -73 | -71 | -51 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 44.55 | 27.09 | 25.79 | 24.87 | 3.63 |
Diluted EPS Before Non-Recurring Items | -1.33 | -2.30 | -3.12 | -2.98 | -16.31 |
Diluted Net EPS (GAAP) | -1.33 | -2.30 | -3.12 | -2.98 | -16.31 |
Fiscal Year end for Galera Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 4.21 | 4.58 | 5.18 | 13.39 | 16.81 |
Income After SG&A, R&D, and Dept/Amort Expenses | -4.21 | -4.58 | -5.18 | -13.39 | -16.81 |
Non-Operating Income | 0.15 | 0.20 | 0.29 | 0.41 | 0.49 |
Interest Expense | 0.00 | 0.00 | 0.70 | 2.09 | 4.40 |
Pretax Income | -4.06 | -4.38 | -5.59 | -15.07 | -20.71 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.06 | -4.38 | -5.59 | -15.07 | -20.71 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.06 | -4.38 | -5.59 | -15.07 | -20.71 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 54.39 | 54.39 | 54.39 | 45.48 | 42.92 |
Diluted EPS Before Non-Recurring Items | -0.07 | -0.08 | -0.10 | -0.33 | -0.48 |
Diluted Net EPS (GAAP) | -0.07 | -0.08 | -0.02 | -0.33 | -0.48 |